Biological Products, (No Diagnostic Substances) · DE · CIK 1861123
Eikon Therapeutics develops important medicines for serious unmet medical needs using proprietary technology
Comparable business profile · signals at a glance
In the 90 days to Feb 6, 2026: 5 insiders bought $46.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 6, 2026 | Column Group Opportunity Iii, LpTenPercentOwner | Buy | 1,437,323 | $18.00 | $25.9M |
| Feb 6, 2026 | Column Group Opportunity Iii, LpTenPercentOwner | Buy | 630,881 | $18.00 | $11.4M |
| Feb 6, 2026 | Column Group Opportunity Iii, LpTenPercentOwner | Buy | 49,556 | $18.00 | $892K |
| Feb 4, 2026 | Lux Ventures V, L.P.TenPercentOwner | Buy | 138,888 | $18.00 | $2.5M |
| Feb 4, 2026 | Wolfe JoshDirector,TenPercentOwner | Buy | 138,888 | $18.00 | $2.5M |
| Feb 4, 2026 | Frazier Kenneth CDirector | Buy | 111,111 | $18.00 | $2.0M |
| Feb 4, 2026 | Foresite Capital Opportunity Management V, LlcTenPercentOwner | Buy | 55,555 | $18.00 | $1000K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.